Hualan Biological Engineering Inc
SZSE:002007
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
13.84
24.44
|
Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Hualan Biological Engineering Inc
Income from Continuing Operations
Hualan Biological Engineering Inc
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Hualan Biological Engineering Inc
SZSE:002007
|
Income from Continuing Operations
ÂĄ1.5B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
1%
|
CAGR 10-Years
10%
|
||
Beigene Ltd
HKEX:6160
|
Income from Continuing Operations
-ÂĄ6.7B
|
CAGR 3-Years
16%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
||
Akeso Inc
HKEX:9926
|
Income from Continuing Operations
ÂĄ1.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Income from Continuing Operations
ÂĄ1.2B
|
CAGR 3-Years
22%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
||
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Income from Continuing Operations
ÂĄ1.8B
|
CAGR 3-Years
5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
||
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Income from Continuing Operations
ÂĄ3.7B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
12%
|
CAGR 10-Years
39%
|
Hualan Biological Engineering Inc
Glance View
Hualan Biological Engineering, Inc. engages in the research and development, production, and sale of biological products. The company is headquartered in Xinxiang, Henan and currently employs 2,927 full-time employees. The company went IPO on 2004-06-25. The company also produces vaccine products and biological engineering products. The firm's main products include human albumins, human immunoglobulin for intravenous injection, human immunoglobulin, human coagulation factors, human rabies immunoglobulin, human tetanus immunoglobulin and influenza vaccines, among others. The firm mainly operates its businesses in domestic markets.
See Also
What is Hualan Biological Engineering Inc's Income from Continuing Operations?
Income from Continuing Operations
1.5B
CNY
Based on the financial report for Sep 30, 2024, Hualan Biological Engineering Inc's Income from Continuing Operations amounts to 1.5B CNY.
What is Hualan Biological Engineering Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
10%
Over the last year, the Income from Continuing Operations growth was 3%. The average annual Income from Continuing Operations growth rates for Hualan Biological Engineering Inc have been -9% over the past three years , 1% over the past five years , and 10% over the past ten years .